{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:29:28Z","timestamp":1793694568549,"version":"4.5.1"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8247104651 \u53f7, 82160129 \u53f7"],"award-info":[{"award-number":["8247104651 \u53f7, 82160129 \u53f7"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy has emerged as a preeminent force in the domain of cancer therapeutics and achieved remarkable breakthroughs. Nevertheless, the high resistance has become the most substantial impediment restricting its clinical efficacy. Beta-2 microglobulin (B2M), the light chain of major histocompatibility complex (MHC) class I, plays an indispensable part by presenting tumor antigens to cytotoxic T lymphocytes (CTLs) for exerting anti-tumor effects. Accumulating evidence indicates that B2M mutation\/defect is one of the key mechanisms underlying tumor immunotherapy resistance. Therefore, elucidating the role played by B2M and devising effective strategies to battle against resistance are pressing issues. This review will systematically expound upon them, aiming to provide insight into the potential of B2M as a promising target in anticancer immune response.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1512509","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T01:27:00Z","timestamp":1742520420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaowen","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","author":"Luri-Rey","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-025-00812-0","article-title":"Progress in personalized immunotherapy for patients with brain metastasis","volume":"9","author":"Patel","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12935-025-03655-8","article-title":"A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies","volume":"25","author":"Panahizadeh","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.10.035","article-title":"Recent advances in mRNA-based cancer vaccines encoding immunostimulants and their delivery strategies","volume":"376","author":"Eslami","year":"2024","journal-title":"J Control Release"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122856","article-title":"Recent progress in cancer vaccines and nanovaccines","volume":"314","author":"Poudel","year":"2025","journal-title":"Biomater Mar"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.06.009","article-title":"Vaccine-based immunotherapy and related preclinical models for glioma","volume":"30","author":"Yao","year":"2024","journal-title":"Trends Mol Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102868","article-title":"CAR-T cell therapy for breast cancer: Current status and future perspective","volume":"133","author":"Buono","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.11.076","article-title":"PROTAC delivery in tumor immunotherapy: Where are we and where are we going","volume":"378","author":"Li","year":"2024","journal-title":"J Control Release"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-24-0857","article-title":"The bidirectional interplay between T cell-based immunotherapies and the tumor microenvironment","author":"Pherez-Farah","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the barrier: unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101177","article-title":"Why and how citrate may sensitize Malignant tumors to immunotherapy","volume":"78","author":"Icard","year":"2025","journal-title":"Drug Resist Update"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-22-3023","article-title":"PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells","volume":"83","author":"Exposito","year":"2023","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.617335","article-title":"Progress and challenges of predictive biomarkers for immune checkpoint blockade","volume":"11","author":"Lei","year":"2021","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122766","article-title":"Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy","volume":"313","author":"Wang","year":"2025","journal-title":"Biomaterials"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/bi00615a029","article-title":"Isolation and partial characterization of a beta2-microglobulin-containing, H-2 antigen-like murine serum protein","volume":"17","author":"Kvist","year":"1978","journal-title":"Biochemistry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.2c00036","article-title":"Lifting the veil: characteristics, clinical significance, and application of \u03b2-2-microglobulin as biomarkers and its detection with biosensors","volume":"8","author":"Sivanathan","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01334","article-title":"Serum \u03b22-microglobulin is closely associated with the recurrence risk and 3-month outcome of acute ischemic stroke","volume":"10","author":"Hu","year":"2019","journal-title":"Front Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.344740","article-title":"Beta 2 microglobulin in kidney failure: A review and an algorithm for renal replacement therapy","volume":"32","author":"Assounga","year":"2021","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.cell.2023.01.021","article-title":"\u03b22-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function","volume":"186","author":"Gao","year":"2023","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10571-024-01481-6","article-title":"The role of beta2-microglobulin in central nervous system disease","volume":"44","author":"Liu","year":"2024","journal-title":"Cell Mol Neurobiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.176084","article-title":"The implication and significance of beta 2 microglobulin: A conservative multifunctional regulator","volume":"129","author":"Li","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1321-6","article-title":"Implication of the \u03b22-microglobulin gene in the generation of tumor escape phenotypes","volume":"61","author":"Bernal","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/his.13895","article-title":"Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial","volume":"75","author":"Barrow","year":"2019","journal-title":"Histopathology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2021.06.008","article-title":"Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy","volume":"517","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13384","article-title":"B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy","volume":"164","author":"Zhao","year":"2021","journal-title":"Immunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.944722","article-title":"The immune-related role of beta-2-microglobulin in melanoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126330","article-title":"The double-edged sword of beta2-microglobulin in antibacterial properties and amyloid fibril-mediated cytotoxicity","volume":"22","author":"Chiou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ckj\/sfy056","article-title":"Using the newer Kidney Disease: Improving Global Outcomes criteria, beta-2-microglobulin levels associate with severity of acute kidney injury","volume":"11","author":"Barton","year":"2018","journal-title":"Clin Kidney J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","article-title":"Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1073\/pnas.1602069113","article-title":"NLRC5\/MHC class I transactivator is a target for immune evasion in cancer","volume":"113","author":"Yoshihama","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2310821121","DOI":"10.1073\/pnas.2310821121","article-title":"Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I","volume":"121","author":"Sun","year":"2024","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e2301975","DOI":"10.1002\/advs.202301975","article-title":"Targeting alpha-ketoglutarate disruption overcomes immunoevasion and improves PD-1 blockade immunotherapy in renal cell carcinoma","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10238-019-00601-7","article-title":"Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer","volume":"20","author":"Snahnicanova","year":"2020","journal-title":"Clin Exp Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.04.002","article-title":"Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation","volume":"9","author":"Woan","year":"2015","journal-title":"Mol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02341-9","article-title":"MHC class-I downregulation in PD-1\/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series","volume":"68","author":"Ugurel","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123690","article-title":"HDAC inhibition increases HLA class I expression in uveal melanoma","volume":"12","author":"Souri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jid.2020.08.023","article-title":"The HDAC inhibitor domatinostat promotes cell-cycle arrest, induces apoptosis, and increases immunogenicity of merkel cell carcinoma cells","volume":"141","author":"Song","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0152","article-title":"Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma","volume":"12","author":"Kalbasi","year":"2020","journal-title":"Sci Transl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/jci153167","article-title":"Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-\u03b3-stimulated antitumor immunity","volume":"132","author":"Ren","year":"2022","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e21776","DOI":"10.1096\/fj.202100235R","article-title":"miR-148a-3p silences the CANX\/MHC-I pathway and impairs CD8(+) T cell-mediated immune attack in colorectal cancer","volume":"35","author":"Zheng","year":"2021","journal-title":"FASEB J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.06.030","article-title":"microRNA 125a regulates MHC-I expression on esophageal adenocarcinoma cells, associated with suppression of antitumor immune response and poor outcomes of patients","volume":"155","author":"Mari","year":"2018","journal-title":"Gastroenterology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179659","article-title":"Predictive biomarkers and resistance mechanisms of checkpoint inhibitors in Malignant solid tumors","volume":"25","author":"Pavelescu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cells14030156","article-title":"Mapping human uterine disorders through single-cell transcriptomics","volume":"14","author":"Boldu-Fern\u00e1ndez","year":"2025","journal-title":"Cells"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104290","article-title":"Applications and emerging challenges of single-cell RNA sequencing technology in tumor drug discovery","volume":"30","author":"Zhang","year":"2025","journal-title":"Drug Discovery Today"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666233","article-title":"High dimensional imaging mass cytometry panel to visualize the tumor immune microenvironment contexture","volume":"12","author":"Elaldi","year":"2021","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859414","article-title":"Application of high-throughput imaging mass cytometry hyperion in cancer research","volume":"13","author":"Le Rochais","year":"2022","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-022-00237-6","article-title":"Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma","volume":"11","author":"Liu","year":"2023","journal-title":"Bone Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.06.064","article-title":"Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts","volume":"161","author":"Bortolomeazzi","year":"2021","journal-title":"Gastroenterology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-3340","article-title":"Biomarker discovery in patients with immunotherapy-treated melanoma with imaging mass cytometry","volume":"27","author":"Martinez-Morilla","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091667","article-title":"Identifying candidate gene drivers associated with relapse in pediatric T-cell acute lymphoblastic leukemia using a gene co-expression network approach","volume":"16","author":"Kypraios","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ggn2.202100060","article-title":"Single-cell transcriptome identifies drug-resistance signature and immunosuppressive microenvironment in metastatic small cell lung cancer","volume":"3","author":"Zhang","year":"2022","journal-title":"Adv Genet (Hoboken)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13287-021-02510-7","article-title":"A deep insight into CRISPR\/Cas9 application in CAR-T cell-based tumor immunotherapies","volume":"12","author":"Razeghian","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-19-1448","article-title":"CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade","volume":"10","author":"Wang","year":"2020","journal-title":"Cancer Discovery"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0287733","DOI":"10.1371\/journal.pone.0287733","article-title":"Generation of murine tumor models refractory to \u03b1PD-1\/-L1 therapies due to defects in antigen processing\/presentation or IFN\u03b3 signaling using CRISPR\/Cas9","volume":"19","author":"Chariou","year":"2024","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discovery"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar3451","article-title":"Tumor immune evasion arises through loss of TNF sensitivity","volume":"3","author":"Kearney","year":"2018","journal-title":"Sci Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2021.01.001","article-title":"In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma","volume":"54","author":"Dubrot","year":"2021","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1016\/j.celrep.2019.08.017","article-title":"Natural killer cells suppress T cell-associated tumor immune evasion","volume":"28","author":"Freeman","year":"2019","journal-title":"Cell Rep"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","article-title":"Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers","volume":"56","author":"Dufva","year":"2023","journal-title":"Immunity"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-23-0139","article-title":"Antitumor immune responses in B2M-deficient cancers","volume":"11","author":"Torrejon","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0987","article-title":"CD4 T cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors","volume":"11","author":"Germano","year":"2021","journal-title":"Cancer Discovery"},{"key":"B75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1946","article-title":"Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition","volume":"23","author":"Pereira","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac268","article-title":"Prevalence and associations of beta2-microglobulin mutations in MSI-H\/dMMR cancers","volume":"28","author":"Liu","year":"2023","journal-title":"Oncologist"},{"key":"B78","doi-asserted-by":"publisher","first-page":"PO.18.00321","DOI":"10.1200\/po.18.00321","article-title":"Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high","volume":"3","author":"Middha","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000417","article-title":"B2M and JAK1\/2-mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy","volume":"45","author":"Zhang","year":"2022","journal-title":"J Immunother"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-18-0683","article-title":"Intrinsic resistance to immune checkpoint blockade in a mismatch repair-deficient colorectal cancer","volume":"7","author":"Gurjao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27848","article-title":"Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation","volume":"11","author":"Khaddour","year":"2020","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-19-1409","article-title":"Overcoming genetically based resistance mechanisms to PD-1 blockade","volume":"10","author":"Torrejon","year":"2020","journal-title":"Cancer Discovery"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1998.tb03082.x","article-title":"Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides","volume":"52","author":"Benitez","year":"1998","journal-title":"Tissue Antigens"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7356","article-title":"Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules","volume":"42","author":"Lhotakova","year":"2019","journal-title":"Oncol Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e1701439","DOI":"10.1002\/adhm.201701439","article-title":"Photothermally controlled MHC class I restricted CD8(+) T-cell responses elicited by hyaluronic acid decorated gold nanoparticles as a vaccine for cancer immunotherapy","volume":"7","author":"Cao","year":"2018","journal-title":"Adv Healthc Mater"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2009.02276.x","article-title":"Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy","volume":"70","author":"Del Campo","year":"2009","journal-title":"Scand J Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","article-title":"Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell Malignancies","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006232","article-title":"CRISPR\/Cas9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma","volume":"6","author":"Guo","year":"2022","journal-title":"Blood Adv"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401683","article-title":"Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR\/Cas9 editing and safety evaluation of the transcriptome","volume":"15","author":"Pavlovic","year":"2024","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-3655","article-title":"Spatial analysis and clinical significance of HLA class-I and class-II subunit expression in non-small cell lung cancer","volume":"27","author":"Datar","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0322-9","article-title":"The inhibitory receptor CD94\/NKG2A on CD8(+) tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE\/\u03b22m overexpression","volume":"33","author":"Eug\u00e8ne","year":"2020","journal-title":"Mod Pathol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-15-3142","article-title":"Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.1038\/s41598-020-64408-3","article-title":"Transcriptional upregulation of NLRC5 by radiation drives STING- and interferon-independent MHC-I expression on cancer cells and T cell cytotoxicity","volume":"10","author":"Zebertavage","year":"2020","journal-title":"Sci Rep"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1757360","article-title":"Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model","volume":"9","author":"Murty","year":"2020","journal-title":"Oncoimmunology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol Int"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B107","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","article-title":"Long-lasting mRNA-encoded interleukin-2 restores CD8(+) T cell neoantigen immunity in MHC class I-deficient cancers","volume":"42","author":"Beck","year":"2024","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1512509\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T01:27:04Z","timestamp":1742520424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1512509\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":107,"alternative-id":["10.3389\/fimmu.2025.1512509"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1512509","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1512509"}}